<DOC>
	<DOCNO>NCT00714025</DOCNO>
	<brief_summary>An open-label , single arm , non-randomized , single stage phase II study . 3 phase : Baseline , treatment/duration Follow-up . All patient treat RAD001 10 mg daily dose disease progression unacceptable toxicity death , discontinuation study , reason</brief_summary>
	<brief_title>A Single Arm , Multicenter , Phase II Trial RAD001 Monotherapy Palliative Treatment Patients With TCC After Failure Chemotherapy</brief_title>
	<detailed_description>An open-label , single arm , non-randomized , single stage phase II study . Baseline phase : Baseline evaluation perform within 2 week first dose study drug . Treatment phase/duration treatment : All patient treat RAD001 10mg PO daily dose disease progression ( RECIST ) unacceptable toxicity death discontinuation study reason . Follow-up phase : All patient follow-up visit schedule 28 day last dose study drug follow AEs SAEs may occur discontinuation study . Any patient discontinue treatment RAD001 reason disease progression continue tumor assessment patient document disease progression start additional anti-tumor therapy . Central radiology review survival data collection perform . After discontinuation RAD001 patient follow survival final OS analysis perform .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients histologicallyor cytologicallyconfirmed locally advanced metastatic TCC amenable curative surgery radiation . Patients document disease progression firstline platinum base therapy interval 4 week since last cytotoxic chemotherapy , biological therapy , surgery radiotherapy patient least one measurable lesion baseline per RECIST criterion ECOG performance status 02 Adequate bone marrow function Adequate liver function Adequate renal function Life expectancy 3 month Women childbearing age must negative pregnancy test within 72 hour prior administration study treatment start Signed informed consent prior begin protocol specific procedure Age 18 year old Patients receive 2 systemic treatment metastatic disease Patients previously receive mTOR inhibitor Patients know hypersensitivity RAD001 rapamycin recipient Patients brain leptomeningeal metastases Patients receive chronic systemic treatment corticosteroid another immunosuppressive agent Patients know history HIV seropositivity Patients autoimmune hepatitis patient active , bleeding diathesis Patients severe and/or uncontrolled medical condition condition could affect participation study Patients history another primary malignancy 5 year Patients use investigational agent receive investigational drug 4 week prior study treatment start Patients unwilling unable comply protocol Female patient pregnant breast feeding , adult reproductive potential use effective birth control method . If barrier contraceptive use , must continue throughout trial sex . Oral contraceptive acceptable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>RAD001</keyword>
	<keyword>TCC</keyword>
	<keyword>Palliative treatment</keyword>
	<keyword>advance metastatic TCC</keyword>
	<keyword>Failure Platinum-based chemotherapy</keyword>
</DOC>